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Longitudinal studyObjective: Meta-analyses of cross-sectional studies confirm an increase in circulating inflammatory
markers during acute psychosis. Longitudinal studies are scarce but are needed to understand whether
elevated inflammatory markers are a cause or consequence of illness. We report a longitudinal study
of serum C-reactive protein (CRP) in adolescence and subsequent risk of schizophrenia and related psy-
choses in adulthood in the Northern Finland Birth Cohort 1986.
Method: Serum high-sensitivity CRP was measured at age 15/16 years in 6362 participants. ICD-10 diag-
noses of schizophrenia and related psychoses were obtained from centralised hospital inpatient and out-
patient registers up to age 27 years. Logistic regression calculated odds ratios (ORs) for psychotic
outcomes associated with baseline CRP levels analysed as both continuous and categorical variables using
American Heart Association criteria. Age, sex, body mass index, maternal education, smoking, and alcohol
use were included as potential confounders.
Results: By age 27 years, 88 cases of non-affective psychosis (1.38%), of which 22 were schizophrenia
(0.35%), were identified. Adolescent CRP was associated with subsequent schizophrenia. The adjusted
OR for schizophrenia by age 27 years for each standard deviation (SD) increase in CRP levels at age
15/16 years was 1.25 (95% CI, 1.07–1.46), which was consistent with a linear, dose-response relationship
(P-value for quadratic term 0.23). Using CRP as a categorical variable, those with high (>3 mg/L) com-
pared with low (<1 mg/L) CRP levels at baseline were more likely to develop schizophrenia; adjusted
OR 4.25 (95% CI, 1.30–13.93). There was some indication that higher CRP was associated with earlier
onset of schizophrenia (rs = 0.40; P = 0.07).
Conclusions: A longitudinal association between adolescent CRP levels and adult schizophrenia diagnosis
indicates a potentially important role of inflammation in the pathogenesis of the illness, although thehildren;
; ICD-10,
254 S.A. Metcalf et al. / Brain, Behavior, and Immunity 59 (2017) 253–259findings, based on a small number of cases, need to be interpreted with caution and require replication in
other samples.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
A possible association between schizophrenia and the immune
system was postulated over a century ago and is supported by epi-
demiological and genetic studies pointing to links with infection
and with alteration in different components of the immune sys-
tem; reviewed (Khandaker et al., 2015a; Khandaker and Dantzer,
2016). Schizophrenia is associated with increased prevalence of
various infections, including the intracellular parasite Toxoplasma
gondii (Torrey et al., 2007) and neurotropic viruses from the Her-
pesviridae family (Bartova et al., 1987; Delisi et al., 1986). System-
atic reviews (Khandaker et al., 2012, 2013) of population-based
studies suggest prenatal maternal infection (Brown et al., 2004a;
Brown and Derkits, 2010; Buka et al., 2001a; Khandaker et al.,
2013; Mortensen et al., 2007), raised inflammatory markers during
pregnancy (Brown et al., 2004b; Buka et al., 2001b; Canetta et al.,
2014), and childhood infections (Benros et al., 2011; Dalman
et al., 2008; Khandaker et al., 2015b) are associated with psychotic
disorders in adulthood and sub-clinical psychotic experiences (PEs)
in adolescence. Similarly, infection/inflammation is associated
with cognitive impairments in schizophrenia patients (Dickerson
et al., 2012, 2008) and impaired neurodevelopment and beha-
vioural problems in experimental animal models of prenatal
immune activation (Meyer et al., 2008; Shi et al., 2009; Weir
et al., 2015). Atopic disorder and autoimmunity, which reflect
alterations in adaptive immune responses, are associated with
adult schizophrenia (Eaton et al., 2006; Karlsson et al., 2012;
Pedersen et al., 2012; Steiner et al., 2013) and adolescent PEs
(Khandaker et al., 2014b).
There is convincing evidence that schizophrenia is associated
with activation of the innate immune response (Di Nicola et al.,
2013; Miller et al., 2011, 2013). Meta-analyses of a large number
of cross-sectional studies confirm that both antipsychotic-naïve
first-episode psychosis and acute psychotic relapse are associated
with increased serum levels of acute phase proteins, such as
C-reactive protein (CRP), and proinflammatory cytokines, such as
interleukin 1 beta (IL-1b), IL-6, and tumour necrosis factor alpha
(TNFa), and decreased serum levels of the anti-inflammatory
cytokine IL-10, all of which tend to normalise after remission of
symptoms with antipsychotic treatment (Goldsmith et al., 2016;
Miller et al., 2011, 2013; Potvin et al., 2008; Upthegrove et al.,
2014). However, it is difficult to ascertain the direction of associa-
tion between inflammation and schizophrenia from cross-sectional
data. Longitudinal studies of inflammatory markers and subse-
quent psychotic illness are scarce but are necessary to establish
whether the increase in circulating inflammatory markers is a
cause or consequence of illness.
Recently, a prospective study from the Avon Longitudinal Study
of Parents and Children (ALSPAC), a general population birth
cohort, has reported two-fold increased risk of PEs and psychotic
disorder at age 18 years for higher serum levels of IL-6 at age
9 years (Khandaker et al., 2014a). Similarly, another population-
based longitudinal study from Denmark has reported an increased
risk of late- or very-late-onset schizophrenia in participants with
higher serum CRP at baseline (Wium-Andersen et al., 2014). While
these studies point towards an important role for systemic
inflammation in the aetiology of psychosis, early- or late-onset
cases may not be representative of all psychosis, the majority ofwhich is incident in early adulthood. In order to examine the
association between inflammation and schizophrenia, we have car-
ried out a longitudinal study of serum CRP levels assessed at age
15/16 years and subsequent hospitalisation for schizophrenia and
related psychosis until age 27 years in the Northern Finland Birth
Cohort (NFBC) 1986. We hypothesised that higher CRP levels in
adolescence would be associated with greater risk for schizophre-
nia in adulthood.2. Method
2.1. Description of the cohort and sample
The NFBC 1986 is a general population-based longitudinal birth
cohort study based on all pregnant women from the two northern-
most provinces of Finland (Oulu and Lapland) with expected dates
of delivery between July 1985 and June 1986 (http://kelo.oulu.fi/
NFBC/). It consists of 9432 live births, which is 99% of all deliveries
in the region during the study period. A wide variety of social and
biological characteristics of the mother and family were recorded
during pregnancy in antenatal clinics. Since birth, data have been
collected by a number of means, including local midwives, three
postal questionnaires (age 7, 8 and 16 years), and face-to-face
assessment clinics, as well as from various hospital records and
routine statistical registers. The current study is based on 6362
participants who had their serum CRP levels measured in blood
samples collected during physical assessment at age 15/16 years.
All participants and their parent(s) gave written informed consent.
The ethical committee of the Northern Ostrobothnia hospital
district provided ethical approval for the NFBC 1986. Data protec-
tion is underpinned by the principles of the Finnish Ministry of
Health and Social Affairs and has been scrutinized by the Privacy
Protection Agency, Finland.2.2. Measurement of CRP at age 15/16 years
Data on serum CRP levels measured in blood samples collected
at age 15/16 years were available from the cohort, which were
used for the current study. We could not include any other acute
phase proteins or cytokines as these had not been measured. For
CRP measurement blood samples were collected after overnight
fasting during clinical assessment at age 15/16 years. Serum
high-sensitivity CRP levels were measured by a quantitative,
immunofluorometric method (Innotrac Aio!; Innotrac Diagnostics
Ltd., Turku, Finland) (Hedberg et al., 2004). In the total sample,
CRP values ranged from 0.01 to 48.23 mg/L. The minimum detec-
tion limit was 0.003 mg/L, which represents the lowest measure-
able analytic level for CRP that can be distinguished from zero.
Those below detection limit were assigned a value of zero
(n = 15; 0.23% of sample) and were also included in analysis.
In addition to analysing CRP as a continuous measure, a cate-
gorical variable for CRP was created based on the American Heart
Association (AHA) and the Centers for Disease Control and Preven-
tion (CDC), USA, guidelines on the use of high-sensitivity CRP levels
in epidemiological studies (Pearson et al., 2003; Salazar et al.,
2014; Yeh andWillerson, 2003). The sample was divided into three
S.A. Metcalf et al. / Brain, Behavior, and Immunity 59 (2017) 253–259 255groups based on serum CRP levels (<1 mg/L = ‘‘low”; 1–3 mg/
L = ‘‘medium”; >3 mg/L = ‘‘high”).
2.3. Diagnosis of schizophrenia and non-affective psychosis
Cases of non-affective psychosis including schizophrenia were
ascertained mainly from the Finnish hospital discharge register
(FHDR) from 1994 (average cohort age 8 years) until the end of
2012 (average cohort age 27 years). Hospital outpatient (1998–
2012) and healthcare outpatient (2011–2012) registers were
searched for additional cases. Diagnoses in the FHDR are made
according to the International Classification of Diseases, 10th revi-
sion, (ICD-10) criteria (WHO, 1992) and have been shown to be
highly specific and reliable (see discussion) (Perala et al.,
2007; Pihlajamaa et al., 2008); non-affective psychosis included
schizophrenia, schizoaffective disorder, and other non-organic psy-
chotic disorders (ICD-10 codes F-20, F-25 and F-28). Main analyses
were carried out separately for schizophrenia alone and for all non-
affective psychoses including schizophrenia. Post-hoc analyses
were conducted to compare the following groups with each other:
(a) schizophrenia, (b) non-schizophrenia non-affective psychosis,
and (c) no psychosis.
2.4. Assessment of covariates
Age, sex, body mass index (BMI), maternal education, smoking,
and alcohol use were included as potential confounders. Sex was
noted from birth records. Age and body mass index (calculated
as weight in kilograms divided by height in square meters) were
recorded during clinical assessment at the time of blood collection
for CRP. Maternal education was recorded through a parent ques-
tionnaire around the time of clinical assessment and was coded
as a categorical variable. Data on smoking and alcohol use were
collected by a self-reported questionnaire completed by the partic-
ipants around the time of clinical assessment at age 15/16 years
and were coded as categorical variables.
2.5. Statistical analysis
Socio-demographic and other characteristics of the sample at
baseline were compared using one-way analysis of variance for
continuous variables and chi-squared test for categorical variables.
We compared Means and medians of CRP at baseline among three
groups (i.e. schizophrenia, non-schizophrenia non-affective
psychosis, and no psychosis) using one-way analysis of variance
and Kruskal-Wallis test, respectively. For the association between
CRP and psychosis, individuals who did not meet particular case
definitions described above were included in the comparison
group. Thus, all cases of non-affective psychosis except schizophre-Table 1
Baseline characteristics of the sample.
Characteristic CRP at age 15/16 y
Low
(<1 mg/L)
Total participants, No. (%) 5221 (82.1)
Male sex, No. (%) 2644 (50.6)
Age at baseline, mean (SD), years 16.0 (0.38)
Body mass index at baseline, mean (SD), kg/m2 20.7 (2.90)
Mother’s education at baseline, No. (%)
Did not complete school education 225 (5.0)
Completed school education 2703 (60.5)
Taken university entrance test equivalent 1538 (34.4)
Smoking at baseline, ever regular use, No. (%) 961 (19.6)
Alcohol use at baseline, ever use, No. (%) 3617 (73.8)
a One-way analysis of variance for continuous data (age and body mass index); chi-sqnia were included in the comparison group for the analyses of
schizophrenia. CRP was used both as a continuous and a categori-
cal variable. First, using CRP as a continuous variable
(z-transformed), logistic regression calculated the risk of psychotic
outcomes at follow-up for each standard deviation (SD) increase in
CRP levels at age 15/16 years. Nonlinearity of the association
between CRP and subsequent schizophrenia was examined by
including a quadratic term (CRP2) within the logistic regression
model. Secondly, using CRP as a categorical variable, logistic
regression calculated the OR for psychotic outcomes for partici-
pants with medium and high CRP levels at baseline; the group with
low CRP levels was used as reference. All regression models were
adjusted for age, sex, BMI, maternal education, smoking, and
alcohol use.
The association between serum CRP levels at age 15/16 years
and age of onset of schizophrenia was examined using Spearman’s
correlation because neither variable was normally distributed.
Effect of sex on the association between CRP and schizophrenia
was examined. First, confounding by sex was evaluated by adjust-
ing the logistic regression models for sex. Secondly, we replicated
the main analysis (i.e., OR for schizophrenia per SD increase in
CRP) separately for men and women. Finally, we tested for an
interaction between CRP and sex in the logistic regression model
of CRP and schizophrenia.
We carried out a number of additional analyses to examine the
robustness of the association between CRP and schizophrenia. To
exclude reverse causality (i.e., schizophrenia leading to elevated
CRP), we repeated the analyses after removing participants who
had developed schizophrenia within one year of CRP assay. We also
repeated the analyses of CRP and psychosis in three ways using dif-
ferent case and comparison groups: (a) schizophrenia alone versus
no psychosis, which excluded participants with other non-affective
psychoses from the comparison group; (b) non-schizophrenia non-
affective psychosis versus no psychosis, which excluded partici-
pants with schizophrenia from the case group; and (c) schizophre-
nia alone versus non-schizophrenia non-affective psychosis, which
excluded participants with no psychosis from the comparison
group.
3. Results
3.1. Diagnosis of schizophrenia by age 27 years and baseline
characteristics of sample
Out of 6362 participants with CRP assessment at age
15/16 years, 88 were diagnosed with non-affective psychosis by
age 27 years (1.38%), of which 22 were schizophrenia (0.35%).
Higher CRP levels at age 15/16 years were associated with female





730 (11.5) 411 (6.5) –
340 (46.6) 191 (46.5) 0.043
16.0 (0.38) 16.0 (0.37) 0.076
23.0 (4.30) 23.4 (5.75) <0.001
<0.001
30 (5.0) 26 (7.3)
392 (65.1) 251 (70.7)
180 (29.9) 78 (22.0)
204 (30.5) 115 (30.5) <0.001
540 (81.0) 295 (78.7) <0.001
uared test for categorical data (sex, maternal education, smoking, and alcohol use).
Table 2
Baseline CRP Levels at Age 15/16 Years in Groups with and without Psychosis at Follow-up.
Groupsa No. Serum CRP at Age 15/16 Years, mg/L
No. (%) with CRP >10 mg/L Range Mean (SD) P-value Median (IQR) P-value
Schizophrenia 22 3 (13.64) 0.03–24.18 2.73 (6.13) 0.022b 0.34 (0.08–0.66) 0.702c
Non-schizophrenia non-affective psychosis 66 2 (3.03) 0.01–15.18 0.95 (2.31) 0.23 (0.08–0.73)
No psychosis 6274 99 (1.58) 0.00–48.23 0.94 (2.79) 0.22 (0.09–0.65)
CRP = C-reactive protein; IQR = interquartile range; SD = standard deviation.
a Diagnosis according to the International Classification of Diseases, 10th revision.
b Means were formally compared using the one-way analysis of variance.
c Medians were formally compared using the Kruskal-Wallis test.
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significantly different among groups with and without psychosis
at follow-up; those with schizophrenia had higher CRP levels at
baseline compared with the other groups (Table 2).
3.2. Association between CRP at age 15/16 years and schizophrenia
diagnosis by age 27 years
Serum CRP levels at age 15/16 years were associated with risk
of schizophrenia by age 27 years. Using CRP as a continuous mea-
sure, the OR for schizophrenia at age 27 years for each SD increase
in CRP level at age 15/16 years was 1.22 (95% CI, 1.05–1.42), which
remained significant after adjusting for potential confounders;
adjusted OR 1.25 (95% CI, 1.07–1.46); P = 0.004. The quadratic term
for CRP within the logistic regression model for CRP andNote: CRP levels at age 15/16 years categorised as “low,” “medi
Fig. 1. Cases of psychotic disorders at age 27 years g
Table 3
ORs for schizophrenia and non-affective psychosis by age 27 years for serum CRP levels a
Outcome CRP Level No. Psychotic, No. (%) OR (95
Unadju
Schizophrenia
Low (<1 mg/L) 5221 17 (0.33) 1 [Refe
Medium (1–3 mg/L) 730 1 (0.14) 0.42 (0
High (>3 mg/L) 411 4 (0.97) 3.01 (1
Non-affective psychosis (including schizophrenia)
Low (<1 mg/L) 5221 68 (1.30) 1 [Refe
Medium (1–3 mg/L) 730 11 (1.51) 1.16 (0
High (>3 mg/L) 411 9 (2.19) 1.70 (0
a Adjusted for sex.
b Adjusted for sex, age, body mass index, and maternal education.
c Adjusted for sex, age, body mass index, maternal education, smoking, and alcohol uschizophrenia was non-significant (P = 0.23), indicating no depar-
ture from linearity. Using CRP as a categorical variable according
to the AHA/CDC definitions, there were more cases of schizophre-
nia in the group with high CRP at baseline compared with the
group with low CRP (Fig. 1). Those with high CRP at age
15/16 years compared with those with low CRP had over four
times the odds of schizophrenia by age 27 years (adjusted OR
4.25; 95% CI, 1.30–13.93) (Table 3).
3.3. Association between CRP at age 15/16 years and all non-affective
psychosis by age 27 years
Serum CRP levels were not associated with all non-affective
psychosis as a whole. Using CRP as a continuous measure, the OR
for all non-affective psychosis for each SD increase in CRP wasum,” and “high” according to AHA/CDC criteria
rouped by serum CRP levels at age 15/16 years.
t age 15/16 years.
% CI)
sted Model 1a Model 2b Model 3c
rence] 1 [Reference] 1 [Reference] 1 [Reference]
.06–3.16) 0.44 (0.06–3.28) 0.52 (0.07–4.10) 0.52 (0.07–4.11)
.01–8.98) 3.13 (1.05–9.37) 3.87 (1.20–2.49) 4.25 (1.30–13.93)
rence] 1 [Reference] 1 [Reference] 1 [Reference]
.61–2.20) 1.18 (0.62–2.24) 1.40 (0.70–2.82) 1.38 (0.68–2.80)
.84–3.43) 1.73 (0.86–3.49) 1.96 (0.91–4.23) 1.82 (0.79–4.17)
se.
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was a nearly two-fold increase in the odds of all non-affective psy-
chosis for participants with high CRP at baseline compared with
low CRP; however, this was not statistically significant (adjusted
OR 1.82; 95% CI, 0.79–4.17) (Fig. 1 and Table 3).3.4. Association between CRP at age 15/16 years and age of onset of
schizophrenia
Mean (SD) age of onset for 22 cases of schizophrenia was 23.26
(3.41) years. Serum CRP levels were negatively correlated with age
of onset (rs = 0.40; P = 0.07), suggesting that higher CRP levels at
age 15/16 years were associated with earlier illness onset (Fig. 2).
Further analysis after excluding two participants with very early
age of onset still indicated a negative correlation between CRP
levels and age of onset of schizophrenia; however, the strength
of the association was reduced (rs = 0.28; P = 0.23).3.5. Effect of sex on the association between CRP and schizophrenia
There was no evidence of a sex difference in the association
between CRP and schizophrenia. In the total sample, evidence for
an association between CRP and schizophrenia remained after
adjusting for sex (Table 3). In stratified analyses, the OR for
schizophrenia by age 27 years for each SD increase in serum CRP
levels at age 15/16 years was 1.22 (95% CI, 1.02–1.46) for men,
and 1.21 (95% CI, 0.91–1.62) for women. Of note, out of 22 cases
of schizophrenia, only 6 were women, so the analysis for women
lacked statistical power as reflected by wider confidence intervals.
Furthermore, the statistical test for interaction between CRP and
sex in the logistic regression model of CRP and schizophrenia
was not significant (P = 0.60).3.6. Post-hoc analyses after excluding schizophrenia cases diagnosed
within a year of CRP measurement
One individual developed schizophrenia within one year of
baseline assessment for CRP. The association between CRP and
schizophrenia remained after excluding this participant; the
adjusted OR for schizophrenia by age 27 years for each SD increase
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Fig. 2. Scatterplot of serum CRP level at age 15/16 years and onset of schizophrenia.3.7. Post-hoc analyses comparing (a) schizophrenia, (b) non-
schizophrenia non-affective psychosis, and (c) no psychosis
Analyses of (a) schizophrenia compared to (c) no psychosis
excluded participants with non-schizophrenia non-affective
psychosis from the comparison group and did not alter the results
of the association between CRP and schizophrenia (see Online Sup-
plementary Tables 1 and 2).
Excluding schizophrenia from the case group yielded a compar-
ison of (b) non-schizophrenia non-affective psychosis against (c)
no psychosis. All 66 cases of non-schizophrenia non-affective psy-
chosis were diagnosed with other non-organic psychotic disorders,
three of whom also received a diagnosis of schizoaffective disorder.
CRP levels at age 15/16 years were not associated with future non-
schizophrenia non-affective psychosis (see Online Supplementary
Tables 3 and 4).
Further analyses comparing (a) schizophrenia against (b) non-
schizophrenia non-affective psychosis yielded similar results to
the original analyses, i.e. higher CRP at baseline was associated
with increased risk of schizophrenia at follow-up. However, due
to small number of participants (22 cases of schizophrenia com-
pared against 66 cases of other psychosis) these new analyses
lacked statistical power, so the 95% confidence intervals for these
ORs include the null (see Online Supplementary Tables 5 and 6).
Five participants with baseline serum CRP levels >1 mg/L at age
15/16 years developed schizophrenia by age 27 years. A table of
their characteristics shows that these participants predominantly
were male, did not regularly smoke or consumed alcohol, and
had mothers who completed school education (see Online Supple-
mentary Table 7). However, it should be noted that due to the very
small number of cases involved these characteristics may or may
not be useful for future investigations.4. Discussion
To our knowledge this is one of the first longitudinal studies of a
systemic inflammatory marker and subsequent risk of schizophre-
nia in adulthood. The findings indicate a longitudinal association
between higher serum CRP levels in adolescence and subsequent
schizophrenia at follow-up until age 27 years, which persists after
taking into account important confounders such as sex, age, body
mass index, maternal education, smoking, and alcohol use. There
was also some evidence that higher adolescent CRP levels were
associated with earlier age of onset for schizophrenia. There was
no evidence for a sex difference in the association between CRP
and schizophrenia. Evidence for an association with CRP remained
after excluding participants who developed schizophrenia within a
year of CRP measurement. Despite a large number of cross-
sectional studies dating back to the 1990s (Ganguli et al., 1994;
Maes et al., 1994) as well as meta-analyses (Miller et al., 2011,
2013; Potvin et al., 2008; Upthegrove et al., 2014) reporting
increased CRP and inflammatory cytokines in acutely unwell
patients with schizophrenia, longitudinal studies are scarce
(Gardner et al., 2013; Khandaker et al., 2014a; Wium-Andersen
et al., 2014). Results from the current study reporting a longitudi-
nal association indicate a potentially important role of inflamma-
tion in the pathogenesis of schizophrenia, although the findings,
based on a limited number of cases, need to be interpreted with
caution and require replication in other samples.
Findings from the current study are in line with two recent
longitudinal studies of systemic inflammatory markers and subse-
quent psychotic outcomes. One study from the general population-
based ALSPAC birth cohort has reported that higher serum levels of
the proinflammatory cytokine IL-6 at age 9 years confer a two-fold
risk of developing psychotic disorder (operationally defined) and
258 S.A. Metcalf et al. / Brain, Behavior, and Immunity 59 (2017) 253–259sub-clinical PEs at age 18 years, though no associations were
observed with CRP. The use of diagnosis of schizophrenia as the
outcome in the current study might account for this difference. A
longitudinal study from Denmark has reported an increased risk
of late- or very-late-onset schizophrenia at follow-up for higher
serum CRP levels at baseline (Wium-Andersen et al., 2014). The
current study adds to these previous findings by reporting a
longitudinal association between an inflammatory marker and
subsequent schizophrenia diagnosis at follow-up nearing the end
of the third decade of life, when the majority of psychosis cases
emerge. The findings might indicate a specific association between
schizophrenia and CRP, which was not associated with other non-
affective psychosis (non-schizophrenia); this category mainly
included non-organic psychotic disorders.
The longitudinal design, use of a general population birth cohort
based on an ethnically homogenous and geographically defined
region, and robust assessments for the exposure and outcome are
some of the key strengths of the study. In addition to hospital
admission, we have used two outpatient registers to identify cases
of psychosis. The coverage of these registers is good (age 8–
27 years). The validity of schizophrenia diagnosis in the FHDR is
comparable with that of other Nordic registers. A study looking
at the accuracy of diagnosis of schizophrenia in the FHDR found
that about 80% of participants with a core schizophrenia spectrum
diagnosis (e.g., schizophrenia or schizoaffective disorder) also
received an ICD-10 core schizophrenia spectrum diagnosis on re-
assessment (Pihlajamaa et al., 2008). A systematic review of 32
studies examining the FHDR has reported high completeness of
the register, which includes over 95% of all admissions (Sund,
2012). A limitation of the study is missing data. About a third of
adult schizophrenia and related psychosis cases were absent from
the assessment at 15/16 years, so they did not have data on CRP
levels at baseline. We did not have any data on history of infection
around the time of blood collection, so possible confounding of the
CRP-schizophrenia relationship by infection cannot be ruled out.
Other potential confounders include physical illness and parental
psychiatric history. However, at age 15/16 years all cohort partici-
pants were physically well enough to attend a voluntary research
follow-up clinic. Most individuals who develop schizophrenia do
not have a positive family history (Gottesman and Sheilds, 1982).
No other blood samples from childhood or adolescence were avail-
able to examine long-term within-individual consistency of CRP
level. However, a large meta-analysis has reported that the
decade-to-decade consistency of CRP is similar to that of blood
pressure and total serum cholesterol concentration, suggesting
that it is sufficiently stable for potential use in long-term disease
prediction (Danesh et al., 2004).
Some of the therapeutic effects of antipsychotics may be due to
their action on inflammation-related pathways (Myint et al.,
2011). A clearer understanding of the immunological aspects of
schizophrenia might lead to novel approaches to treatment and
diagnosis. Randomised controlled trials (RCTs) of celecoxib (a
COX-2 inhibitor) and aspirin as adjunct to antipsychotic treatment
have shown encouraging results in schizophrenia (Laan et al.,
2010; Muller et al., 2002; Sommer et al., 2014). Minocycline, a cen-
trally acting tetracyclic anti-inflammatory agent, has been reported
to improve negative symptoms and cognitive function in
schizophrenia (Chaudhry et al., 2012; Levkovitz et al., 2010). Activa-
tion of the inflammatory system is associated with resistance to
antipsychotic treatment (Mondelli et al., 2015), so stratification of
patients according to their immune phenotypemight aid prediction
of treatment response. This strategy was useful in a recent RCT of
infliximab (a TNFa antagonist) in treatment-resistant depression.
In this trial no overall efficacy of infliximab was observed, but it
improved depressive symptoms in patients with higher levels of
CRP at the start of the trial (Raison et al., 2013).In conclusion, we report a longitudinal association between a
circulating inflammatory marker in adolescence and subsequent
risk of schizophrenia in adulthood, which may suggest an impor-
tant role for inflammation in the pathogenesis of the illness.
Inflammatory pathways may offer important new prevention and
intervention targets for schizophrenia.
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